Reverse Lipid Droplet Function for Hepatocellular Carcinoma Immunotherapy

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Lipid droplets (LDs) play a crucial role in tumor progression and immune evasion.
• Targeting LDs directly for cancer therapy remains a significant challenge.
• A correlation exists between LD-related proteins and poor prognosis in hepatocellular carcinoma (HCC) patients.

Purpose of the Study:

• To develop a novel strategy to reverse LD function for HCC immunotherapy.
• To investigate the potential of LD-organelle networks as immunotherapy targets.
• To explore a new approach for treating metastatic tumors through organelle-level metabolic disruption.

Main Methods:

• Engineered F127-modified, linoleic acid (LA)-capped copper MOF nanoparticles (LCMF NPs).
• Utilized CD36 receptor-mediated endocytosis for NP internalization into LDs.
• Leveraged copper ions and Fenton reaction to catalyze LA peroxidation, reversing LD function.

Main Results:

• LCMF NPs induced oxidative damage within LDs, triggering DNA damage.
• Upregulated key immunogenic cell death markers (HMGB1, calreticulin).
• In vivo studies demonstrated reshaping of the immunosuppressive tumor microenvironment and inhibition of primary and distant tumor growth.

Conclusions:

• Reversing LD function is a viable immunotherapy strategy for HCC.
• LD-organelle networks can be targeted for cancer treatment.
• This approach shows promise for treating metastatic tumors via metabolic disruption.